Michael Staehler
YOU?
Author Swipe
View article: Final analysis of lenvatinib + pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma with or without bone metastases in CLEAR
Final analysis of lenvatinib + pembrolizumab vs. sunitinib in patients with advanced renal cell carcinoma with or without bone metastases in CLEAR Open
View article: Head‐to‐head comparison of <scp>TKI</scp> and <scp>CPI</scp> first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform <scp>CARAT</scp>
Head‐to‐head comparison of <span>TKI</span> and <span>CPI</span> first‐line treatment strategies in advanced renal cell carcinoma—Real‐world data from the German research platform <span>CARAT</span> Open
The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of he…
View article: Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy
Renal Cell Carcinoma: Prognosis in the Era of Targeted Therapy Open
Background: Significant changes in renal cell carcinoma (RCC) drug treatment and improved access to abdominal imaging have recently been implemented. The impact of these changes on patient characteristics and prognosis remains to be quanti…
View article: Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma
Changes of Prostate-Specific Membrane Antigen-Radioligand Uptake on PET with Systemic Therapy in Patients with Metastatic Renal Cell Carcinoma Open
Background/Objectives: Early treatment assessment in metastatic renal cell carcinoma (mRCC) remains challenging due to the limited accuracy of current imaging methods. Given prostate-specific membrane antigen (PSMA) overexpression in mRCC,…
View article: Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma
Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma Open
Immune checkpoint therapy (ICI) has enabled induction of remission in advanced renal cell carcinoma RCC. ICI toxicities can persist as chronic health conditions. We developed a patient survey to assess changes in medical comorbidities afte…
View article: Perioperative Outcomes After Radical Nephrectomy with Inferior Vena Cava Thrombectomy
Perioperative Outcomes After Radical Nephrectomy with Inferior Vena Cava Thrombectomy Open
Background and Objective: We aimed to evaluate current trends and complications after radical nephrectomy with inferior vena cava (IVC) thrombectomy and to provide evidence on the role of the annual hospital caseload on perioperative outco…
View article: Prognosis of Renal Cell Carcinoma in the Era Oftargeted Therapy: A Nationwide Observational Cohort Study of Patients Diagnosed in Germany Between 2000-2019
Prognosis of Renal Cell Carcinoma in the Era Oftargeted Therapy: A Nationwide Observational Cohort Study of Patients Diagnosed in Germany Between 2000-2019 Open
View article: Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma.
Patient Perspective on Medical Conditions Post Immune Checkpoint Therapy in Advanced Renal Carcinoma. Open
Immune checkpoint therapy (ICI) has enabled induction of remission in advanced renal cell carcinoma RCC. ICI toxicities can persist as chronic health conditions. We developed a patient survey to assess changes in medical comorbidities afte…
View article: Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the <scp>CLEAR</scp> trial
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the <span>CLEAR</span> trial Open
Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc analysis of tumor response data ba…
View article: A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE) Open
Second- or later-line cabozantinib was effective and manageable in a real-world setting and had a safety profile consistent with previous studies.
View article: P179 Lenvatinib plus Pembrolizumab (L+P) vs. Sunitinib (S) in advanced Renal Cell Carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
P179 Lenvatinib plus Pembrolizumab (L+P) vs. Sunitinib (S) in advanced Renal Cell Carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial Open
View article: Evolution of Robotic Urology in Clinical Practice from the Beginning to Now: Results from the GRAND Study Register
Evolution of Robotic Urology in Clinical Practice from the Beginning to Now: Results from the GRAND Study Register Open
Patients selected for robotic surgery in Germany presented better perioperative outcomes compared to those operated with an open approach.
View article: Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey
Financial Distress in Genitourinary Cancer: Insights From CDC National Health Interview Survey Open
PURPOSE This study leverages CDC National Health Interview Survey data to examine Financial Distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and bladder cancer (BC). It investi…
View article: Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy Open
Many patients diagnosed with cancer adopt dietary changes and supplement use, and a growing body of evidence suggests that such modifications can affect outcomes to cancer therapy. We sought to assess the prevalence of these practices and …
View article: Surgical Trends and Complications in Partial and Radical Nephrectomy: Results from the GRAND Study
Surgical Trends and Complications in Partial and Radical Nephrectomy: Results from the GRAND Study Open
Background: We aimed to evaluate the current trends in renal cancer surgery, as well as to compare the perioperative outcomes of partial versus radical nephrectomy. Methods: We used the GeRmAn Nationwide inpatient Data (GRAND), provided by…
View article: PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches
PSMA-Expression Is Highly Associated with Histological Subtypes of Renal Cell Carcinoma: Potential Implications for Theranostic Approaches Open
In renal cell carcinoma (RCC), accurate imaging methods are required for treatment planning and response assessment to therapy. In addition, there is an urgent need for new therapeutic options, especially in metastatic RCC. One way to comb…
View article: Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial
Tumor Response by Baseline Metastases in Patients (Pts) With Renal Cell Carcinoma (RCC) Treated with Lenvatinib (L) Plus Pembrolizumab (P) vs Sunitinib (S): Post Hoc Analysis of the CLEAR Trial Open
View article: 1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial
1903P Tumor response by baseline metastases in patients (pts) with renal cell carcinoma (RCC) treated with lenvatinib (L) plus pembrolizumab (P) vs sunitinib (S): Post hoc analysis of the CLEAR trial Open
View article: Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial Open
View article: Quantitative differentiation of minimal-fat angiomyolipomas from renal cell carcinomas using grating-based x-ray phase-contrast computed tomography: An ex vivo study
Quantitative differentiation of minimal-fat angiomyolipomas from renal cell carcinomas using grating-based x-ray phase-contrast computed tomography: An ex vivo study Open
Background The differentiation of minimal-fat—or low-fat—angiomyolipomas from other renal lesions is clinically challenging in conventional computed tomography. In this work, we have assessed the potential of grating-based x-ray phase-cont…
View article: Table S1 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Table S1 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis Open
Allele frquency
View article: Supplementary Figure S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Supplementary Figure S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
The gene/gene groups and algorithm included in calculating the RS. The RS is derived from the reference-normalized expression measurements, scaled from 0 to 100: Unscaled RS = -0.45 Ã- VN group score -0.31 Ã- IR group score + 0.27 Ã- CGD g…
View article: Data from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Data from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
Purpose: Adjuvant sunitinib prolonged disease-free survival (DFS; HR, 0.76) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov NCT00375674). The 16-gene Recurrence Score (RS) a…
View article: Table S4 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Table S4 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis Open
Comparison of OS stratified by genotype and treatment group
View article: Supplementary Table S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Supplementary Table S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
Patient baseline characteristics in the placebo versus sunitinib arm: all T3 patients in the gene signature cohort. aN0 or NX, any Fuhrman grade, ECOG PS 0 or Fuhrman grade 1 and ECOG PS ï,³1. bN0 or NX, Fuhrman grade {greater than or equa…
View article: Supplementary Table S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Supplementary Table S1 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
Patient baseline characteristics in the placebo versus sunitinib arm: all T3 patients in the gene signature cohort. aN0 or NX, any Fuhrman grade, ECOG PS 0 or Fuhrman grade 1 and ECOG PS ï,³1. bN0 or NX, Fuhrman grade {greater than or equa…
View article: Data from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Data from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
Purpose: Adjuvant sunitinib prolonged disease-free survival (DFS; HR, 0.76) in patients with locoregional high-risk renal cell carcinoma (RCC) in the S-TRAC trial (ClinicalTrials.gov NCT00375674). The 16-gene Recurrence Score (RS) a…
View article: Supplementary Figure S2 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Supplementary Figure S2 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
Distribution of RS results in T3 patients in the gene signature cohort. Abbreviations: RS, recurrence score; T3, stage III tumor.
View article: Supplementary Figure S2 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib
Supplementary Figure S2 from Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib Open
Distribution of RS results in T3 patients in the gene signature cohort. Abbreviations: RS, recurrence score; T3, stage III tumor.
View article: Table S3 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Table S3 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis Open
Association between DFS and genotype subgroups within each treatment group or the combined sunitinib and placebo groups